10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 401–500 of 1,169
Reference Values of Skin Autofluorescence
Koetsier, M., Lutgers, H. L., de Jonge, C., Links, T. P., Smit, A. J., & Graaff, R. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0113 · Cited by 214
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 220
Johansen, O., Neubacher, D., von Eynatten, M., Patel, S., & Woerle, H.-J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-3 · Cited by 220
“Common criteria across the Phase 3 trials included a diagnosis of inadequately controlled T2DM, age ≥ 18 years and, in most studies, body mass index (BMI) ≤ 40 kg/m2.”
InfluentialAmerican Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s008 · Cited by 215
“Long-term follow-up of the UKPDS cohorts showed enduring effects of early glycemic control on most microvascular complications (37).”
BackgroundLarge and Small Artery Cross-Talk and Recent Morbidity-Mortality Trials in Hypertension
Laurent, S., Briet, M., & Boutouyrie, P. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.133116 · Cited by 217
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
Kim, M. K., Ko, S.-H., Kim, B.-Y., Kang, E. S., Noh, J., Kim, S.-K., Park, S.-O., Hur, K. Y., Chon, S., Moon, M. K., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0137 · Cited by 216
Tian, J., Zhang, M., Suo, M., Liu, D., Wang, X., Liu, M., Pan, J., Jin, T., & An, F. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16601 · Cited by 212
Minimizing Hypoglycemia in Diabetes
International Hypoglycaemia Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0279 · Cited by 209
“Hypoglycemia Given documented evidence that glycemic control partially prevents or delays microvascular complications (retinopathy, nephropathy, and neuropathy) in type 1 diabetes (69) and type 2 diabetes (44,45,96,97) and might partially prevent or delay some macrovascular complications in type 1 diabetes (98) and ty…”
BackgroundFrederich, R., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R., Wolf, R., & Mahaffey, K. W. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2138 · Cited by 217
Ali, M. K., Bullard, K. M., Saydah, S., Imperatore, G., & Gregg, E. W. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30027-5 · Cited by 208
Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing
Hua, Y., Zheng, Y., Yao, Y., Jia, R., Ge, S., & Zhuang, A. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04263-8 · Cited by 199
Glucose, Obesity, Metabolic Syndrome, and Diabetes
Horwich, T. B., & Fonarow, G. C. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.029 · Cited by 206
Epigenetics: Mechanisms and Implications for Diabetic Complications
Cooper, M. E., & El-Osta, A. (2010) · Circulation Research · doi:10.1161/circresaha.110.223552 · Cited by 213
Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline
Klonoff, D. C., Buckingham, B., Christiansen, J. S., Montori, V. M., Tamborlane, W. V., Vigersky, R. A., & Wolpert, H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2756 · Cited by 211
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211
Welsh, K. J., Kirkman, M. S., & Sacks, D. B. (2016) · Diabetes Care · doi:10.2337/dc15-2727 · Cited by 207
“The role of HbA1c in diabetes has been extensively studied in large, prospective trials with long-term follow-up (9,10), which has extensively validated the value of HbA1c in predicting many diabetic complications.”
BackgroundGlycemic Monitoring and Management in Advanced Chronic Kidney Disease
Galindo, R. J., Beck, R. W., Scioscia, M. F., Umpierrez, G. E., & Tuttle, K. R. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa017 · Cited by 202
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub3 · Cited by 203
RetractedSelective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes
Sharabi, K., Lin, H., Tavares, C. D. J., Dominy, J. E., Camporez, J. P., Perry, R. J., Schilling, R., Rines, A. K., Lee, J., Hickey, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.001 · Cited by 210
Review of methods for detecting glycemic disorders
Bergman, M., Abdul-Ghani, M., DeFronzo, R. A., Manco, M., Sesti, G., Fiorentino, T. V., Ceriello, A., Rhee, M., Phillips, L. S., Chung, S., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108233 · Cited by 199
“Glucose criteria, especially the 2-h PG, have greater sensitivity than HbA1c in diagnosing diabetes in the majority of cohorts [27,28,45-51] each diagnosing distinct patient populations.”
BackgroundZhang, Y., Liu, C., Luo, S., Xie, Y., Liu, F., Li, X., & Zhou, Z. (2019) · Journal of Medical Internet Research · doi:10.2196/15023 · Cited by 207
“Optimal glycemic control can prevent diabetes-related complications [3].”
Type 2 diabetes as a redox disease
Watson, J. D. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62365-x · Cited by 206
Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control
Hirst, J. A., Farmer, A. J., Ali, R., Roberts, N. W., & Stevens, R. J. (2012) · Diabetes Care · doi:10.2337/dc11-1465 · Cited by 204
Lachin, J. M., Orchard, T. J., Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2116 · Cited by 206
“Of note, the one trial in type 2 diabetes that has demonstrated a benefit of intensive diabetes management on CVD outcomes, the UK Prospective Diabetes Study (19), recruited a relatively young population with new-onset diabetes, reduced HbA1c to approximately 7%, and followed the subjects postintervention, similar to…”
ResultHollander, P., Li, J., Allen, E., Chen, R., & for the CV181-013 Investigators (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0550 · Cited by 208
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s009 · Cited by 205
“Long-term follow-up of the UKPDS cohorts showed enduring effects of early glycemic control on most microvascular complications (34).”
BackgroundPrimary Prevention of Cardiovascular Disease in Diabetes Mellitus
Newman, J. D., Schwartzbard, A. Z., Weintraub, H. S., Goldberg, I. J., & Berger, J. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.001 · Cited by 205
“Earlier RCTs of patients with T1D and T2D demonstrated a 25% to 70% reduction in microvascular disease along with nonsignificant reductions in macrovascular disease (58,59), that required 10þ years of follow-up to reach statistical significance for CVD risk reduction (60).”
BackgroundKhunti, K., Ceriello, A., Cos, X., & De Block, C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.004 · Cited by 200
Lower extremity arterial disease in patients with diabetes: a contemporary narrative review
Nativel, M., Potier, L., Alexandre, L., Baillet-Blanco, L., Ducasse, E., Velho, G., Marre, M., Roussel, R., Rigalleau, V., & Mohammedi, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0781-1 · Cited by 194
Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review
Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J. (2025) · JAMA · doi:10.1001/jama.2025.5956 · Cited by 204
Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
Saisho, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018381 · Cited by 195
“control has been shown to reduce the development of CVD as well as diabetic microangiopathy during long-term follow up in patients with both type 1 (T1DM) and type 2 diabetes (T2DM), so-called legacy effects [3,4].”
BackgroundShould metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 181
The use of metformin in type 1 diabetes: a systematic review of efficacy
Vella, S., Buetow, L., Royle, P., Livingstone, S., Colhoun, H. M., & Petrie, J. R. (2010) · Diabetologia · doi:10.1007/s00125-009-1636-9 · Cited by 201
“Importantly metformin therapy was associated with a substantial 33% reduction in the rate of myocardial infarction in people with type 2 diabetes in the UKPDS, and this was sustained to 10 years after the end of randomisation [14].”
BackgroundPrecision medicine in the management of type 2 diabetes
Gloyn, A. L., & Drucker, D. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30052-4 · Cited by 183
Jiang, K., Xu, Y., Wang, D., Chen, F., Tu, Z., Qian, J., Xu, S., Xu, Y., Hwa, J., Li, J., et al. (2022) · Protein & Cell · doi:10.1007/s13238-020-00809-4 · Cited by 187
Maahs, D. M., Daniels, S. R., de Ferranti, S. D., Dichek, H. L., Flynn, J., Goldstein, B. I., Kelly, A. S., Nadeau, K. J., Martyn-Nemeth, P., Osganian, S. K., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000094 · Cited by 194
Mannucci, E., Monami, M., Lamanna, C., Gori, F., & Marchionni, N. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.021 · Cited by 201
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s233538 · Cited by 177
“follow-up extension of Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) studies.(40,41) Instead, in CVOTs on SGLT2i, the event-free survival curves separated soon after randomization, especially in patients wi…”
BackgroundBergman, M., Manco, M., Satman, I., Chan, J., Schmidt, M. I., Sesti, G., Vanessa Fiorentino, T., Abdul-Ghani, M., Jagannathan, R., Kumar Thyparambil Aravindakshan, P., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111589 · Cited by 171
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
RAGE biology, atherosclerosis and diabetes
Barlovic, D. P., Soro-Paavonen, A., & Jandeleit-Dahm, K. A. M. (2011) · Clinical Science · doi:10.1042/cs20100501 · Cited by 195
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Sheahan, K. H., Wahlberg, E. A., & Gilbert, M. P. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137186 · Cited by 194
Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes
The ACCORD Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2283 · Cited by 193
“9% reduced the 18-year incidence of myocardial infarction by 15% and death by 13% in people with newly diagnosed type 2 diabetes (24).”
Backgroundon behalf of the AdRem* project team and ADVANCE management committee, Beulens, J. W. J., Patel, A., Vingerling, J. R., Cruickshank, J. K., Hughes, A. D., Stanton, A., Lu, J., McG Thom, S. A., Grobbee, D. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1457-x · Cited by 188
“Similarly, the UKPDS recently reported that, despite a loss of glycaemic differences, the reduced risk of microvascular disease continued and risk reductions for myocardial infarction and death emerged during 10 years of post-trial follow-up [26].”
BackgroundTherapeutic interventions for aging: the case of cellular senescence
Soto-Gamez, A., & Demaria, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.004 · Cited by 192
Potential Bioactive Compounds from Seaweed for Diabetes Management
Sharifuddin, Y., Chin, Y.-X., Lim, P.-E., & Phang, S.-M. (2015) · Marine Drugs · doi:10.3390/md13085447 · Cited by 187
Mijnhout, G. S., Kollen, B. J., Alkhalaf, A., Kleefstra, N., & Bilo, H. J. G. (2012) · International Journal of Endocrinology · doi:10.1155/2012/456279 · Cited by 186
“There is overwhelming evidence that the development of microvascular complications is related to the level of glucose dysregulation over a long period of time [2].”
BackgroundEmerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy
Zhang, Y., Sun, X., Icli, B., & Feinberg, M. W. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1122 · Cited by 183
Zhao, M., Song, L., Sun, L., Wang, M., Wang, C., Yao, S., Li, Y., Yun, C., Zhang, S., Sun, Y., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2375 · Cited by 186
“Previous studies have reported that patients with type 2 diabetes can benefit considerably from intensive therapy for the prevention of CVD and death (39,40).”
BackgroundJohnston, S. S., Conner, C., Aagren, M., Smith, D. M., Bouchard, J., & Brett, J. (2011) · Diabetes Care · doi:10.2337/dc10-1915 · Cited by 189
“005), even after an intensive strategy was abandoned (1,8).”
BackgroundGlycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Goldberg, R. B., Orchard, T. J., Crandall, J. P., Boyko, E. J., Budoff, M., Dabelea, D., Gadde, K. M., Knowler, W. C., Lee, C. G., Nathan, D. M., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056756 · Cited by 173
Powell, D. R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., Mseeh, F., Shadoan, M. K., Sands, A., Zambrowicz, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203364 · Cited by 184
“Treatments that control blood glucose in these patients decrease complications (UK Prospective Diabetes Study Group, 1998a,b; Holman et al., 2008; Ray et al., 2009).”
BackgroundCastagno, D., Baird-Gunning, J., Jhund, P. S., Biondi-Zoccai, G., MacDonald, M. R., Petrie, M. C., Gaita, F., & McMurray, J. J. V. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.030 · Cited by 190
Karalliedde, J., & Gnudi, L. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu405 · Cited by 183
Active Care Management Supported by Home Telemonitoring in Veterans With Type 2 Diabetes
Stone, R. A., Rao, R. H., Sevick, M. A., Cheng, C., Hough, L. J., Macpherson, D. S., Franko, C. M., Anglin, R. A., Obrosky, D. S., & DeRubertis, F. R. (2010) · Diabetes Care · doi:10.2337/dc09-1012 · Cited by 185
“482 DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 care.diabetesjournals.org abetes Trial, 10-year follow-up results from the UK Prospective Diabetes Study (10) indicated that intensive glycemic control established earlier in the course of type 2 diabetes does reduce subsequent cardiovascular events, even though the d…”
BackgroundPreiss, D., Lloyd, S. M., Ford, I., McMurray, J. J., Holman, R. R., Welsh, P., Fisher, M., Packard, C. J., & Sattar, N. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70152-9 · Cited by 187
Self-citationSecondary stroke prevention: challenges and solutions
Gutierrez, J., & Esenwa, C. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s63791 · Cited by 177
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 181
Cornel, J. H., Bakris, G. L., Stevens, S. R., Alvarsson, M., Bax, W. A., Chuang, L.-M., Engel, S. S., Lopes, R. D., McGuire, D. K., Riefflin, A., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1415 · Cited by 186
“Microvascular complication rates are related to HbA1c levels (21), and can be reducedwith improved glycemic control (22,23), but in TECOS there was only a small difference in HbA1c levels between treatment groups because the study”
BackgroundSelf-citation7. Approaches to Glycemic Treatment
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s010 · Cited by 181
“Metformin has a longstanding evidence base for efficacy and safety, is inexpensive, and may reduce risk of cardiovascular events and death (18).”
BackgroundVilleneuve, L. M., Kato, M., Reddy, M. A., Wang, M., Lanting, L., & Natarajan, R. (2010) · Diabetes · doi:10.2337/db10-0208 · Cited by 186
Chan, S. M. H., Selemidis, S., Bozinovski, S., & Vlahos, R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.013 · Cited by 177
“In addition, the use of this drug has also been found to reduce risk of cardiovascular events and mortalities (Holman, Paul, Bethel, Matthews, & Neil, 2008) , despite the occurrence of lactic acidosis in rare cases (Frid et al., 2010) .”
BackgroundMetabolic memory: mechanisms and diseases
Dong, H., Sun, Y., Nie, L., Cui, A., Zhao, P., Leung, W. K., & Wang, Q. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01755-x · Cited by 214
“10 Furthermore, 160 participants with T2DM and microalbuminuria (with a mean age of 55) were randomized and allocated to undergo either conventional or intensive therapy in the Steno-2 trial, and they were followed for the mean 13.3-year duration.”
BackgroundMethodInfluentialElam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Evans, M., Welsh, Z., Ells, S., & Seibold, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00720-0 · Cited by 185
Vijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2894 · Cited by 185
Glycemic Management of Type 2 Diabetes Mellitus
Ismail-Beigi, F. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1013127 · Cited by 177
Guideline for management of postmeal glucose in diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.08.002 · Cited by 183
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M. C., Rydén, L., Xavier, D., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13028 · Cited by 183
A Cascade of Care for Diabetes in the United States: Visualizing the Gaps
Ali, M. K., Bullard, K. M., Gregg, E. W., & del Rio, C. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0019 · Cited by 182
Opportunities and challenges in using real-world data for health care
Rudrapatna, V. A., & Butte, A. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129197 · Cited by 174
“For instance, 10-year and 30-year follow-up data from the UK Prospective Diabetes Study and the Diabetes Control and Complications Trial, of type 2 and type 1 diabetes mellitus, respectively, have demonstrated a long-term reduction in disease complications following a strategy of intensive glycemic control (41, 42).”
BackgroundJapanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12810 · Cited by 181
Prevalence of diabetes in the Malaysian National Health Morbidity Survey III 2006.
Letchuman, G. R., Nazaimoon, W. M. W., Mohamad, W. B. W., Chandran, L., Tee, G. H., Jamaiyah, H., Isa, M. R., Zanariah, H., Fatanah, I., & Yusoff, A. F. (2010) · PubMed · Cited by 250
(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70155-x · Cited by 183
Impaired insulin signalling and allostatic load in Alzheimer disease
De Felice, F. G., Gonçalves, R. A., & Ferreira, S. T. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-022-00558-9 · Cited by 177
Anti-diabetic drugs and weight loss in patients with type 2 diabetes
Lazzaroni, E., Ben Nasr, M., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105782 · Cited by 182
“The subsequent addition of metformin to sulphonylurea treatment in a subgroup of patients in this trial did not result in a significant weight change [21].”
BackgroundKhunti, S., Khunti, K., & Seidu, S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819844694 · Cited by 182
Reaven, P. D., Moritz, T. E., Schwenke, D. C., Anderson, R. J., Criqui, M., Detrano, R., Emanuele, N., Kayshap, M., Marks, J., Mudaliar, S., et al. (2009) · Diabetes · doi:10.2337/db09-0618 · Cited by 182
“This may also explain the more favorable results in the UK Prospective Diabetes Study, which evaluated improved glucose control in patients with newly diagnosed diabetes (6,20).”
ResultInsulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“in terms of reduced diabetes-related endpoints, diabetesrelated deaths, and all-cause mortality.[169] Along with”
BackgroundLiu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180
Blonde, L., Merilainen, M., Karwe, V., Raskin, P., & TITRATE™ Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01060.x · Cited by 180
Epigenetics and Epigenomics: Implications for Diabetes and Obesity
Rosen, E. D., Kaestner, K. H., Natarajan, R., Patti, M.-E., Sallari, R., Sander, M., & Susztak, K. (2018) · Diabetes · doi:10.2337/db18-0537 · Cited by 171
“Studies of patients with type 2 diabetes have found similar benefits of strict glycemic control (35).”
BackgroundNewman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
EADSG Guidelines: Insulin Therapy in Diabetes
Silver, B., Ramaiya, K., Andrew, S. B., Fredrick, O., Bajaj, S., Kalra, S., Charlotte, B. M., Claudine, K., & Makhoba, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0384-6 · Cited by 179
“Key areas in insulin therapy discussed in the guidelines include insulin regimen in patients with T1DM, a stepwise approach to insulin initiation, titration, and intensification in patients with T2DM, self-monitoring of blood glucose (SMBG), awareness and management of hypoglycemia, weight gain with intensive insulin…”
BackgroundInfluentialMetabolic surgery for the treatment of type 2 diabetes in obese individuals
Cummings, D. E., & Rubino, F. (2018) · Diabetologia · doi:10.1007/s00125-017-4513-y · Cited by 179
“Given the known benefits of tight vs standard glycaemic control in early diabetes on long-term cardiovascular disease (‘legacy effect’) [7, 8], even among people whose diabetes relapses several years after metabolic surgery, it is possible that this disease-free interval will also yield long-term cardiovascular benefi…”
BackgroundDiabetic Retinopathy: An Overview on Mechanisms, Pathophysiology and Pharmacotherapy
Ansari, P., Tabasumma, N., Snigdha, N. N., Siam, N. H., Panduru, R., Azam, S., Hannan, J. M. A., & Abdel‐Wahab, Y. H. A. (2022) · Diabetology · doi:10.3390/diabetology3010011 · Cited by 213
“However, the reverse action of extreme damage usually caused to the microvascular retinal cells cannot be easily done, even with highly intensive treatment and efficient glycemic control [15,29].”
BackgroundThe Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0024 · Cited by 178
Secondary Failure of Metformin Monotherapy in Clinical Practice
Brown, J. B., Conner, C., & Nichols, G. A. (2010) · Diabetes Care · doi:10.2337/dc09-1749 · Cited by 178
“Long-term observational follow-up of the UK Prospective Diabetes Study cohort showed that intensively treated patients maintained lower risks for any diabetesrelated end point, microvascular disease, myocardial infarction, and all-cause mortality well after between-group differences in glycemic control disappeared (11…”
BackgroundAdvanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes
Yamagishi, S.-I., Nakamura, N., Suematsu, M., Kaseda, K., & Matsui, T. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00067 · Cited by 173
“Prospective Diabetes Study (UKPDS), called UKPDS80, has also shown that benefits of an intensive therapy in patients with type 2 diabetes are sustained after the cessation of the trial (18).”
BackgroundDiabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches
Madonna, R., Balistreri, C. R., Geng, Y.-J., & De Caterina, R. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.01.004 · Cited by 170
Diabetes mellitus and stroke: A clinical update
Tun, N. N., Arunagirinathan, G., Munshi, S. K., & Pappachan, J. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.235 · Cited by 177
Insulin therapy and hypoglycemia
McCall, A. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.001 · Cited by 177
Roumie, C. L., Greevy, R. A., Grijalva, C. G., Hung, A. M., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2014) · JAMA · doi:10.1001/jama.2014.4312 · Cited by 173
“12 961 (8) 191 (8) 0 Baseline Comorbidities, No.”
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 176
The emerging challenge in diabetes: The “metabolic memory”
Ceriello, A. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.05.005 · Cited by 170
“…fewer adverse clinical outcomes over time as compared to people in the standard treatment, despite similar rates of HbA1c in the long follow-up that followed the end of the study (Holman et al., 2008), suggesting that early metabolic control has enduring beneficial effects even in type 2 diabetes.”
Barnett, A. H., Huisman, H., Jones, R., von Eynatten, M., Patel, S., & Woerle, H.-J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61500-7 · Cited by 183
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
Home, P., Riddle, M., Cefalu, W. T., Bailey, C. J., Bretzel, R. G., del Prato, S., Leroith, D., Schernthaner, G., van Gaal, L., & Raz, I. (2014) · Diabetes Care · doi:10.2337/dc13-2743 · Cited by 167
“microvascular complications and, in the long-term, improve cardiovascular prognosis (7,10).”
BackgroundRodríguez-Gutiérrez, R., & Montori, V. M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002901 · Cited by 176
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.